Association of serum soluble Receptor for Advanced Glycation End-products with subclinical cerebrovascular disease: The Northern Manhattan Study (NOMAS)

Barry I. Hudson, Yeseon Park Moon, Anastasia Z. Kalea, Minesh Khatri, Chensy Marquez, Ann Marie Schmidt, Myunghee C. Paik, Mitsuhiro Yoshita, Ralph L. Sacco, Charles DeCarli, Clinton B. Wright, Mitchell S V Elkind

Research output: Contribution to journalArticle

47 Citations (Scopus)

Abstract

Objective: Serum levels of the soluble Receptor for Advanced Glycation End-products (sRAGE) have been associated with risk of cardiovascular disease. We hypothesized that sRAGE levels are associated with subclinical cerebrovascular disease in an ethnically diverse population. Methods: Clinically stroke-free participants in the multi-ethnic Northern Manhattan Study (NOMAS) underwent brain MRI to quantify subclinical brain infarcts (SBI) and white matter hyperintensity volume (WMHV) (n= 1102). Serum levels of sRAGE were measured by ELISA. Logistic and multiple linear regression were employed to estimate associations of sRAGE with SBI and WMHV, after adjusting for demographics and vascular risk factors. Results: Median sRAGE levels were significantly lower in Hispanics (891.9. pg/ml; n= 708) and non-Hispanic blacks (757.4. pg/ml; n= 197) than in non-Hispanic whites (1120.5. pg/ml; n= 170), and these differences remained after adjusting for other risk factors. Interactions were observed by race-ethnicity between sRAGE levels and MRI measurements, including for SBI in Hispanics (p= 0.04) and WMHV among blacks (p= 0.03). In Hispanics, increasing sRAGE levels were associated with a lower odds of SBI, with those in the upper sRAGE quartile displaying a 50% lower odds of SBI after adjusting for sociodemographic and vascular risk factors (p= 0.05). Among blacks, those in the upper quartile of sRAGE had a similarly reduced increased risk of SBI (p= 0.06) and greater WMHV (p= 0.04). Conclusion: Compared to whites, Hispanics and blacks have significantly lower sRAGE levels, and these levels were associated with more subclinical brain disease. Taken together, these findings suggest sRAGE levels may be significantly influence by ethnicity. Further studies of sRAGE and stroke risk, particularly in minorities, are warranted.

Original languageEnglish (US)
Pages (from-to)192-198
Number of pages7
JournalAtherosclerosis
Volume216
Issue number1
DOIs
StatePublished - May 2011

Fingerprint

Cerebrovascular Disorders
Serum
Hispanic Americans
Brain
Advanced Glycosylation End Product-Specific Receptor
Stroke
Brain Diseases
Linear Models
Cardiovascular Diseases

Keywords

  • Biological marker
  • Hispanics
  • MRI
  • RAGE (Receptor for Advanced Glycation End-products)
  • Subclinical infarct
  • White matter hyperintensities

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Association of serum soluble Receptor for Advanced Glycation End-products with subclinical cerebrovascular disease : The Northern Manhattan Study (NOMAS). / Hudson, Barry I.; Moon, Yeseon Park; Kalea, Anastasia Z.; Khatri, Minesh; Marquez, Chensy; Schmidt, Ann Marie; Paik, Myunghee C.; Yoshita, Mitsuhiro; Sacco, Ralph L.; DeCarli, Charles; Wright, Clinton B.; Elkind, Mitchell S V.

In: Atherosclerosis, Vol. 216, No. 1, 05.2011, p. 192-198.

Research output: Contribution to journalArticle

Hudson, BI, Moon, YP, Kalea, AZ, Khatri, M, Marquez, C, Schmidt, AM, Paik, MC, Yoshita, M, Sacco, RL, DeCarli, C, Wright, CB & Elkind, MSV 2011, 'Association of serum soluble Receptor for Advanced Glycation End-products with subclinical cerebrovascular disease: The Northern Manhattan Study (NOMAS)', Atherosclerosis, vol. 216, no. 1, pp. 192-198. https://doi.org/10.1016/j.atherosclerosis.2011.01.024
Hudson, Barry I. ; Moon, Yeseon Park ; Kalea, Anastasia Z. ; Khatri, Minesh ; Marquez, Chensy ; Schmidt, Ann Marie ; Paik, Myunghee C. ; Yoshita, Mitsuhiro ; Sacco, Ralph L. ; DeCarli, Charles ; Wright, Clinton B. ; Elkind, Mitchell S V. / Association of serum soluble Receptor for Advanced Glycation End-products with subclinical cerebrovascular disease : The Northern Manhattan Study (NOMAS). In: Atherosclerosis. 2011 ; Vol. 216, No. 1. pp. 192-198.
@article{08fe789a36e043c5aa692487b8c774a3,
title = "Association of serum soluble Receptor for Advanced Glycation End-products with subclinical cerebrovascular disease: The Northern Manhattan Study (NOMAS)",
abstract = "Objective: Serum levels of the soluble Receptor for Advanced Glycation End-products (sRAGE) have been associated with risk of cardiovascular disease. We hypothesized that sRAGE levels are associated with subclinical cerebrovascular disease in an ethnically diverse population. Methods: Clinically stroke-free participants in the multi-ethnic Northern Manhattan Study (NOMAS) underwent brain MRI to quantify subclinical brain infarcts (SBI) and white matter hyperintensity volume (WMHV) (n= 1102). Serum levels of sRAGE were measured by ELISA. Logistic and multiple linear regression were employed to estimate associations of sRAGE with SBI and WMHV, after adjusting for demographics and vascular risk factors. Results: Median sRAGE levels were significantly lower in Hispanics (891.9. pg/ml; n= 708) and non-Hispanic blacks (757.4. pg/ml; n= 197) than in non-Hispanic whites (1120.5. pg/ml; n= 170), and these differences remained after adjusting for other risk factors. Interactions were observed by race-ethnicity between sRAGE levels and MRI measurements, including for SBI in Hispanics (p= 0.04) and WMHV among blacks (p= 0.03). In Hispanics, increasing sRAGE levels were associated with a lower odds of SBI, with those in the upper sRAGE quartile displaying a 50{\%} lower odds of SBI after adjusting for sociodemographic and vascular risk factors (p= 0.05). Among blacks, those in the upper quartile of sRAGE had a similarly reduced increased risk of SBI (p= 0.06) and greater WMHV (p= 0.04). Conclusion: Compared to whites, Hispanics and blacks have significantly lower sRAGE levels, and these levels were associated with more subclinical brain disease. Taken together, these findings suggest sRAGE levels may be significantly influence by ethnicity. Further studies of sRAGE and stroke risk, particularly in minorities, are warranted.",
keywords = "Biological marker, Hispanics, MRI, RAGE (Receptor for Advanced Glycation End-products), Subclinical infarct, White matter hyperintensities",
author = "Hudson, {Barry I.} and Moon, {Yeseon Park} and Kalea, {Anastasia Z.} and Minesh Khatri and Chensy Marquez and Schmidt, {Ann Marie} and Paik, {Myunghee C.} and Mitsuhiro Yoshita and Sacco, {Ralph L.} and Charles DeCarli and Wright, {Clinton B.} and Elkind, {Mitchell S V}",
year = "2011",
month = "5",
doi = "10.1016/j.atherosclerosis.2011.01.024",
language = "English (US)",
volume = "216",
pages = "192--198",
journal = "Atherosclerosis",
issn = "0021-9150",
publisher = "Elsevier Ireland Ltd",
number = "1",

}

TY - JOUR

T1 - Association of serum soluble Receptor for Advanced Glycation End-products with subclinical cerebrovascular disease

T2 - The Northern Manhattan Study (NOMAS)

AU - Hudson, Barry I.

AU - Moon, Yeseon Park

AU - Kalea, Anastasia Z.

AU - Khatri, Minesh

AU - Marquez, Chensy

AU - Schmidt, Ann Marie

AU - Paik, Myunghee C.

AU - Yoshita, Mitsuhiro

AU - Sacco, Ralph L.

AU - DeCarli, Charles

AU - Wright, Clinton B.

AU - Elkind, Mitchell S V

PY - 2011/5

Y1 - 2011/5

N2 - Objective: Serum levels of the soluble Receptor for Advanced Glycation End-products (sRAGE) have been associated with risk of cardiovascular disease. We hypothesized that sRAGE levels are associated with subclinical cerebrovascular disease in an ethnically diverse population. Methods: Clinically stroke-free participants in the multi-ethnic Northern Manhattan Study (NOMAS) underwent brain MRI to quantify subclinical brain infarcts (SBI) and white matter hyperintensity volume (WMHV) (n= 1102). Serum levels of sRAGE were measured by ELISA. Logistic and multiple linear regression were employed to estimate associations of sRAGE with SBI and WMHV, after adjusting for demographics and vascular risk factors. Results: Median sRAGE levels were significantly lower in Hispanics (891.9. pg/ml; n= 708) and non-Hispanic blacks (757.4. pg/ml; n= 197) than in non-Hispanic whites (1120.5. pg/ml; n= 170), and these differences remained after adjusting for other risk factors. Interactions were observed by race-ethnicity between sRAGE levels and MRI measurements, including for SBI in Hispanics (p= 0.04) and WMHV among blacks (p= 0.03). In Hispanics, increasing sRAGE levels were associated with a lower odds of SBI, with those in the upper sRAGE quartile displaying a 50% lower odds of SBI after adjusting for sociodemographic and vascular risk factors (p= 0.05). Among blacks, those in the upper quartile of sRAGE had a similarly reduced increased risk of SBI (p= 0.06) and greater WMHV (p= 0.04). Conclusion: Compared to whites, Hispanics and blacks have significantly lower sRAGE levels, and these levels were associated with more subclinical brain disease. Taken together, these findings suggest sRAGE levels may be significantly influence by ethnicity. Further studies of sRAGE and stroke risk, particularly in minorities, are warranted.

AB - Objective: Serum levels of the soluble Receptor for Advanced Glycation End-products (sRAGE) have been associated with risk of cardiovascular disease. We hypothesized that sRAGE levels are associated with subclinical cerebrovascular disease in an ethnically diverse population. Methods: Clinically stroke-free participants in the multi-ethnic Northern Manhattan Study (NOMAS) underwent brain MRI to quantify subclinical brain infarcts (SBI) and white matter hyperintensity volume (WMHV) (n= 1102). Serum levels of sRAGE were measured by ELISA. Logistic and multiple linear regression were employed to estimate associations of sRAGE with SBI and WMHV, after adjusting for demographics and vascular risk factors. Results: Median sRAGE levels were significantly lower in Hispanics (891.9. pg/ml; n= 708) and non-Hispanic blacks (757.4. pg/ml; n= 197) than in non-Hispanic whites (1120.5. pg/ml; n= 170), and these differences remained after adjusting for other risk factors. Interactions were observed by race-ethnicity between sRAGE levels and MRI measurements, including for SBI in Hispanics (p= 0.04) and WMHV among blacks (p= 0.03). In Hispanics, increasing sRAGE levels were associated with a lower odds of SBI, with those in the upper sRAGE quartile displaying a 50% lower odds of SBI after adjusting for sociodemographic and vascular risk factors (p= 0.05). Among blacks, those in the upper quartile of sRAGE had a similarly reduced increased risk of SBI (p= 0.06) and greater WMHV (p= 0.04). Conclusion: Compared to whites, Hispanics and blacks have significantly lower sRAGE levels, and these levels were associated with more subclinical brain disease. Taken together, these findings suggest sRAGE levels may be significantly influence by ethnicity. Further studies of sRAGE and stroke risk, particularly in minorities, are warranted.

KW - Biological marker

KW - Hispanics

KW - MRI

KW - RAGE (Receptor for Advanced Glycation End-products)

KW - Subclinical infarct

KW - White matter hyperintensities

UR - http://www.scopus.com/inward/record.url?scp=79955537037&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79955537037&partnerID=8YFLogxK

U2 - 10.1016/j.atherosclerosis.2011.01.024

DO - 10.1016/j.atherosclerosis.2011.01.024

M3 - Article

C2 - 21316677

AN - SCOPUS:79955537037

VL - 216

SP - 192

EP - 198

JO - Atherosclerosis

JF - Atherosclerosis

SN - 0021-9150

IS - 1

ER -